Skip to main content
Erschienen in: Current Urology Reports 11/2015

01.11.2015 | Urothelial Cancer (A Sagalowsky, Section Editor)

Quality of Life Outcomes for Bladder Cancer Patients Undergoing Bladder Preservation with Radiotherapy

verfasst von: Michael A. Feuerstein, Anuj Goenka

Erschienen in: Current Urology Reports | Ausgabe 11/2015

Einloggen, um Zugang zu erhalten

Abstract

For patients with muscle-invasive bladder cancer, the decision to undergo radical cystectomy or bladder preservation treatment must incorporate survival differences, toxicity, and quality of life. Our objective was to review patient-reported outcomes for bladder preservation treatment with a focus on patients eligible for radical cystectomy, for whom a comparison of patient-reported outcomes is most relevant. Peer-reviewed, English-language manuscripts in MEDLINE and PubMed databases were examined from 1996 through 2014. Subject headings included quality of life, bladder cancer, bladder sparing, bladder preservation, radiation, and radiotherapy. Prospective and retrospective studies of patient-reported outcomes in patients undergoing bladder preservation with radiotherapy for muscle-invasive bladder cancer were included. Two prospective studies and four retrospective studies were identified. Several weaknesses from these studies were identified including small sample sizes, variable time points of assessment, variation in treatment regimens, and failure to use validated or condition-specific questionnaires. From the available data, bladder preservation appears to result to similar or better general quality of life compared to radical cystectomy with satisfactory urinary and sexual function reported in most series. In general, bladder preservation resulted in more gastrointestinal symptoms than radical cystectomy. This is one of the first reviews on the subject of patient-reported outcomes for bladder preservation in muscle-invasive bladder cancer. Although the data are limited, this review may provide a framework for developing well-designed, prospective comparisons of treatment for this patient cohort.
Literatur
1.
Zurück zum Zitat Botteman MF, Pashos CL, Hauser RS, et al. Quality of life aspects of bladder cancer: a review of the literature. Qual Life Res. 2003;12:675.CrossRefPubMed Botteman MF, Pashos CL, Hauser RS, et al. Quality of life aspects of bladder cancer: a review of the literature. Qual Life Res. 2003;12:675.CrossRefPubMed
2.
Zurück zum Zitat Porter MP, Penson DF. Health related quality of life after radical cystectomy and urinary diversion for bladder cancer: a systematic review and critical analysis of the literature. J Urol. 2005;173:1318.CrossRefPubMed Porter MP, Penson DF. Health related quality of life after radical cystectomy and urinary diversion for bladder cancer: a systematic review and critical analysis of the literature. J Urol. 2005;173:1318.CrossRefPubMed
3.
Zurück zum Zitat Shabsigh A, Korets R, Vora KC, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol. 2009;55:164.CrossRefPubMed Shabsigh A, Korets R, Vora KC, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol. 2009;55:164.CrossRefPubMed
4.••
Zurück zum Zitat Mak RH, Hunt D, Shipley WU, et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of radiation therapy oncology group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol 2014. This pooled analysis from five prospective bladder-preserving protocols provides a high level of evidence for efficacy and safety of combined-modailty therapy. At a median follow-up of 4.3 years for all patients, 5- and 10-year overall and disease-free survival rates were comparable to similarly staged patients undergoing radical cystectomy. Mak RH, Hunt D, Shipley WU, et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of radiation therapy oncology group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol 2014. This pooled analysis from five prospective bladder-preserving protocols provides a high level of evidence for efficacy and safety of combined-modailty therapy. At a median follow-up of 4.3 years for all patients, 5- and 10-year overall and disease-free survival rates were comparable to similarly staged patients undergoing radical cystectomy.
5.•
Zurück zum Zitat Basch E, Abernethy AP, Mullins CD, et al. Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol. 2012;30:4249. Recommendations for methodological standards for measuring and reporting patient-reported outcomes in comparative effectiveness trials in oncology. Basch E, Abernethy AP, Mullins CD, et al. Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol. 2012;30:4249. Recommendations for methodological standards for measuring and reporting patient-reported outcomes in comparative effectiveness trials in oncology.
6.
Zurück zum Zitat Howie L, Hirsch B, Locklear T, et al. Assessing the value of patient-generated data to comparative effectiveness research. Health Aff (Millwood). 2014;33:1220.CrossRef Howie L, Hirsch B, Locklear T, et al. Assessing the value of patient-generated data to comparative effectiveness research. Health Aff (Millwood). 2014;33:1220.CrossRef
7.
Zurück zum Zitat Henningsohn L, Wijkstrom H, Dickman PW, et al. Distressful symptoms after radical radiotherapy for urinary bladder cancer. Radiother Oncol. 2002;62:215.CrossRefPubMed Henningsohn L, Wijkstrom H, Dickman PW, et al. Distressful symptoms after radical radiotherapy for urinary bladder cancer. Radiother Oncol. 2002;62:215.CrossRefPubMed
8.
Zurück zum Zitat Herman JM, Smith DC, Montie J, et al. Prospective quality-of-life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy. Urology. 2004;64:69.CrossRefPubMed Herman JM, Smith DC, Montie J, et al. Prospective quality-of-life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy. Urology. 2004;64:69.CrossRefPubMed
9.•
Zurück zum Zitat Lagrange JL, Bascoul-Mollevi C, Geoffrois L, et al. Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a multicenter prospective study (GETUG 97–015). Int J Radiat Oncol Biol Phys. 2011;79:172. This prospective trial reported quality-of-life outcomes for bladder-preserving multimodal therapy in patients suitable for radical cystectomy. With a median follow-up of 8 years, the authors report satisfactory quality-of-life and quality of bladder function in two-thirds of patients. Lagrange JL, Bascoul-Mollevi C, Geoffrois L, et al. Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a multicenter prospective study (GETUG 97–015). Int J Radiat Oncol Biol Phys. 2011;79:172. This prospective trial reported quality-of-life outcomes for bladder-preserving multimodal therapy in patients suitable for radical cystectomy. With a median follow-up of 8 years, the authors report satisfactory quality-of-life and quality of bladder function in two-thirds of patients.
10.
Zurück zum Zitat Zietman AL, Sacco D, Skowronski U, et al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol. 2003;170:1772.CrossRefPubMed Zietman AL, Sacco D, Skowronski U, et al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol. 2003;170:1772.CrossRefPubMed
11.
Zurück zum Zitat Caffo O, Fellin G, Graffer U. Assessment of quality of life after cystectomy or conservative therapy for patients with infiltrating bladder carcinoma. a survey by a self-administered questionnaire. Cancer. 1996;78:1089.CrossRefPubMed Caffo O, Fellin G, Graffer U. Assessment of quality of life after cystectomy or conservative therapy for patients with infiltrating bladder carcinoma. a survey by a self-administered questionnaire. Cancer. 1996;78:1089.CrossRefPubMed
12.
Zurück zum Zitat Little FA, Howard GC. Sexual function following radical radiotherapy for bladder cancer. Radiother Oncol. 1998;49:157.CrossRefPubMed Little FA, Howard GC. Sexual function following radical radiotherapy for bladder cancer. Radiother Oncol. 1998;49:157.CrossRefPubMed
13.
Zurück zum Zitat Rodel C, Weiss C. Organ-sparing multimodality treatment for muscle-invasive bladder cancer: can we continue to ignore the evidence? J Clin Oncol. 2014. Rodel C, Weiss C. Organ-sparing multimodality treatment for muscle-invasive bladder cancer: can we continue to ignore the evidence? J Clin Oncol. 2014.
14.
Zurück zum Zitat Efstathiou JA, Bae K, Shipley WU, et al. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89–03, 95–06, 97–06, 99–06. J Clin Oncol. 2009;27:4055.PubMedCentralCrossRefPubMed Efstathiou JA, Bae K, Shipley WU, et al. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89–03, 95–06, 97–06, 99–06. J Clin Oncol. 2009;27:4055.PubMedCentralCrossRefPubMed
15.
Zurück zum Zitat Nutting CM, Convery DJ, Cosgrove VP, et al. Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer. Int J Radiat Oncol Biol Phys. 2000;48:649.CrossRefPubMed Nutting CM, Convery DJ, Cosgrove VP, et al. Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer. Int J Radiat Oncol Biol Phys. 2000;48:649.CrossRefPubMed
16.
Zurück zum Zitat Roeske JC, Bonta D, Mell LK, et al. A dosimetric analysis of acute gastrointestinal toxicity in women receiving intensity-modulated whole-pelvic radiation therapy. Radiother Oncol. 2003;69:201.CrossRefPubMed Roeske JC, Bonta D, Mell LK, et al. A dosimetric analysis of acute gastrointestinal toxicity in women receiving intensity-modulated whole-pelvic radiation therapy. Radiother Oncol. 2003;69:201.CrossRefPubMed
17.
Zurück zum Zitat Sondergaard J, Hoyer M, Petersen JB, et al. The normal tissue sparing obtained with simultaneous treatment of pelvic lymph nodes and bladder using intensity-modulated radiotherapy. Acta Oncol. 2009;48:238.CrossRefPubMed Sondergaard J, Hoyer M, Petersen JB, et al. The normal tissue sparing obtained with simultaneous treatment of pelvic lymph nodes and bladder using intensity-modulated radiotherapy. Acta Oncol. 2009;48:238.CrossRefPubMed
18.
Zurück zum Zitat Calvert M, Blazeby J, Altman DG, et al. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309:814.CrossRefPubMed Calvert M, Blazeby J, Altman DG, et al. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309:814.CrossRefPubMed
Metadaten
Titel
Quality of Life Outcomes for Bladder Cancer Patients Undergoing Bladder Preservation with Radiotherapy
verfasst von
Michael A. Feuerstein
Anuj Goenka
Publikationsdatum
01.11.2015
Verlag
Springer US
Erschienen in
Current Urology Reports / Ausgabe 11/2015
Print ISSN: 1527-2737
Elektronische ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-015-0547-1

Weitere Artikel der Ausgabe 11/2015

Current Urology Reports 11/2015 Zur Ausgabe

Kidney Diseases (G Ciancio, Section Editor)

Robot-assisted Partial Nephrectomy for Endophytic Tumors

Pediatric Urology (M Castellan and R Gosalbez, Section Editors)

Stem Cell Therapy: Current Applications and Potential for Urology

Neu im Fachgebiet Urologie

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.